Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia (vol 396, pg 887, 2020)

Logunov D. Y.; Dolzhikova I. V; Zubkova O. V

首页> 外文期刊>The Lancet >Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia (vol 396, pg 887, 2020)

【24h】

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia (vol 396, pg 887, 2020)

机译：rad26和rad5载体的异源素母型促进咖啡酰-19两种配方的安全性和免疫原性：来自俄罗斯的两个开放式，非随机阶段1/2研究（Vol 396，PG 887,2020）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The Lancet》 |2021年第10269期|共1页
作者
Logunov D. Y.; Dolzhikova I. V; Zubkova O. V;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医药、卫生;
关键词

相似文献

外文文献
中文文献

1. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia (vol 397, pg 671, 2021) [J] . Logunov D. Y., Dolzhikova I. V, Shcheblyakov D. V The Lancet . 2021,第10275期

机译：RAD26和RAD5基于载体的异源素质 - 增压Covid-19疫苗的安全性和有效性：俄罗斯随机对照第3阶段试验的临时分析（Vol 397，PG 671,2021）
2. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia [J] . Logunov Denis Y., Dolzhikova Inna V., Shcheblyakov Dmitry V., The Lancet . 2021,第10275期

机译：RAD26和基于RAD5载体的异源素质促进Covid-19疫苗的安全性和有效性：俄罗斯随机对照第3阶段试验的临时分析
3. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial (vol 396, pg 1979, 2020) [J] . Ramasamy M. N., Minassian A. M., Ewer K. J. The Lancet . 2021,第10282期

机译：在年轻人和老年人的主要升压方案中施用的Chadox1 NCoV-19疫苗的安全性和免疫原性（COV002）：单盲，随机，受控，2/3试验（第396 Vol 396，PG 1979,2020）
4. Safety and immunogenicity of GamEvac-Combi a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia [O] . I. V. Dolzhikova, O. V. Zubkova, A. I. Tukhvatulin, 2017

机译：GamEvac-Combi（一种异源VSV和Ad5载体埃博拉疫苗）的安全性和免疫原性：在俄罗斯健康成年人中进行的开放式I / II试验
5. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia [O] . Denis Y Logunov, Inna V Dolzhikova, Olga V Zubkova, 2020

机译：rad26和rad5载体的异源素母素升压Covid-19的安全性和免疫原性两种配方：来自俄罗斯的两个开放，非随机化阶段1/2研究
6. Phase 1 Study of Safety and Immunogenicity of an Escherichia coli- Derived Recombinant Protective Antigen (rPA) Vaccine to Prevent Anthrax in Adults [R] . Brown, B. K., Cox, J., Gillis, A., 2010

机译：第一阶段研究大肠杆菌源重组保护性抗原（rpa）疫苗的安全性和免疫原性，以预防成人炭疽病

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia (vol 396, pg 887, 2020)

著录项

相似文献

相关主题

期刊订阅